Literature DB >> 6215450

Cell-mediated immunity in untreated and PUVA treated atopic dermatitis.

E Soppi, M Viander, A M Soppi, C T Jansén.   

Abstract

In 22 adult patients with atopic dermatitis, lymphocyte subpopulation counts, mitogenic responses to several PHA and Con A concentrations, nonspecific mitogen induced, and indomethacin sensitive suppressor cell functions and leukocyte migration inhibitory factor production were investigated. Patients with severe atopic dermatitis had normal PHA and Con A responses, although somewhat lower than matched controls, while mild AD patients equalled controls in this respect. No significant differences between AD patients and controls were detected with respect to lymphocyte subpopulations, suppressor cell function or leukocyte migration inhibitory factor production. Methoxalen plus ultraviolet light (PUVA) therapy induced significant clinical improvement in 9 out of 10 treated patients. A concomitant decrease of the mitogenic responses and increase of the Con A induced nonspecific suppressor cell activity was recorded, while other immunological parameters remained unaffected by the therapy. Thus PUVA therapy induces both local clinical and systemic immunological manifestations. The possibility that the observed immunological changes would be operative in the PUVA induced healing process, however, seems unlikely, as the present study did not disclose any obvious relationship between immune parameters and severity of atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6215450     DOI: 10.1111/1523-1747.ep12500063

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  2 in total

Review 1.  Treatment of atopic dermatitis: old and new modalities.

Authors:  A R Rhodes
Journal:  Clin Rev Allergy       Date:  1986-02

2.  Natural killer cell activity in atopic dermatitis.

Authors:  M Viander; J Uksila; O Lassila; C T Jansén
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.